Literature DB >> 23441975

Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.

G Hechmati1, S Cure, A Gouépo, H Hoefeler, V Lorusso, D Lüftner, I Duran, C Garzon-Rodriguez, J Ashcroft, R Wei, P Ghelani, A Bahl.   

Abstract

OBJECTIVES: Patients with bone metastases often experience skeletal-related events (SREs: radiation or surgery to bone, pathologic fracture, and spinal cord compression). This study examined health resource utilization and costs associated with SREs.
METHODS: Data presented are from the European cohort (Germany, Italy, Spain, and the UK) of patients with solid tumours enrolled in a multi-national, prospective, observational study in patients with solid tumours or multiple myeloma. Patients with Eastern Cooperative Oncology Group score 0-2 and life expectancy ≥6 months, who experienced an SRE up to 97 days before enrolment, were eligible. Health resource utilization associated with SREs (including number/length of inpatient stays, numbers of procedures and outpatient visits) were collected through chart review for up to 97 days before enrolment and prospectively during follow-up. Country-specific cost calculations were performed.
RESULTS: In total, 478 eligible patients contributed 893 SREs to this analysis. Radiation to bone occurred most frequently (66% of total). Spinal cord compression (7%) and surgery to bone (10%) were the least common events, but most likely to require inpatient stays. The most costly SREs were also spinal cord compression (mean per SRE across countries, €4884-€12,082) and surgery to bone (€3348-€9407). Inpatient stays were the main cost drivers. LIMITATIONS: Health resource utilization used to calculate the costs associated with SREs may have been under-estimated as a result of exclusion of patients with low performance status or life expectancy; unavailable information and exclusion of resource consumption associated with pain. Thus, the estimate of associated costs is likely to be conservative.
CONCLUSIONS: SREs result in considerable health resource utilization, imposing a substantial financial burden driven by inpatient stays. Treatments that prevent/delay SREs may help ease this burden, thereby providing cost savings across European healthcare systems.

Entities:  

Mesh:

Year:  2013        PMID: 23441975     DOI: 10.3111/13696998.2013.779921

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  24 in total

Review 1.  MRI-guided focused ultrasound surgery in musculoskeletal diseases: the hot topics.

Authors:  Alberto Bazzocchi; Alessandro Napoli; Beatrice Sacconi; Giuseppe Battista; Giuseppe Guglielmi; Carlo Catalano; Ugo Albisinni
Journal:  Br J Radiol       Date:  2015-11-26       Impact factor: 3.039

2.  The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres.

Authors:  Fred Saad; Neil E Fleshner; Alan So; Jacques Le Lorier; Louise Perrault; Melanie Poulin-Costello; Raina Rogoza; Ewan J D Robson
Journal:  Can Urol Assoc J       Date:  2018-06-19       Impact factor: 1.862

3.  Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.

Authors:  Chin-Yao Shen; Philip Chun-Ming Au; Yeon-Hee Baek; Ching-Lung Cheung; Wei-Pang Chung; Ju Hwan Kim; Nora J Kleinman; Tai-Chung Lam; Tzu-Chi Liao; Tzu-Chieh Lin; Ju-Young Shin; Chor-Wing Sing; Ian Chi Kei Wong; Edward Chia-Cheng Lai
Journal:  BioDrugs       Date:  2022-04-12       Impact factor: 5.807

4.  Trends in Diagnosis and Surgical Treatment of Bone Metastases among Orthopedic Surgeons.

Authors:  Dawid Ciechanowicz; Daniel Kotrych; Filip Dąbrowski; Tomasz Mazurek
Journal:  J Clin Med       Date:  2022-07-23       Impact factor: 4.964

5.  Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study.

Authors:  Prue Cormie; Daniel A Galvão; Nigel Spry; David Joseph; Dennis R Taaffe; Robert U Newton
Journal:  Support Care Cancer       Date:  2014-01-15       Impact factor: 3.603

6.  Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study.

Authors:  Vito Lorusso; Ignacio Duran; Cristina Garzon-Rodriguez; Diana Lüftner; Amit Bahl; John Ashcroft; Guy Hechmati; Rachel Wei; Emma Thomas; Herbert Hoefeler
Journal:  Mol Clin Oncol       Date:  2014-06-27

7.  Modular tumor endoprostheses in surgical palliation of long-bone metastases: a reduction in tumor burden and a durable reconstruction.

Authors:  Marcel-Philipp Henrichs; Juliane Krebs; Georg Gosheger; Arne Streitbuerger; Markus Nottrott; Tim Sauer; Steffen Hoell; Gurpal Singh; Jendrik Hardes
Journal:  World J Surg Oncol       Date:  2014-11-07       Impact factor: 2.754

8.  Nationwide epidemiology and healthcare utilization of spine tumor patients in the adult Korean population, 2009-2012.

Authors:  Seil Sohn; Jinhee Kim; Chun Kee Chung; Na-Rye Lee; Eunjung Park; Ung-Kyu Chang; Moon Jun Sohn; Sung Hwan Kim
Journal:  Neurooncol Pract       Date:  2015-05-05

9.  Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study.

Authors:  Amit Bahl; Herbert Hoefeler; Ignacio Duran; Guy Hechmati; Cristina Garzon-Rodriguez; John Ashcroft; Vito Lorusso; Prayashi Ghelani; Rachel Wei; Emma Thomas; Diana Lüftner
Journal:  J Clin Med       Date:  2014-07-29       Impact factor: 4.241

10.  Health resource utilization associated with skeletal-related events: results from a retrospective European study.

Authors:  Jean-Jacques Body; João Pereira; Harm Sleeboom; Nikos Maniadakis; Evangelos Terpos; Yves Pascal Acklin; Jindrich Finek; Oliver Gunther; Guy Hechmati; Tony Mossman; Luis Costa; Wojciech Rogowski; Hareth Nahi; Roger von Moos
Journal:  Eur J Health Econ       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.